Surgery Partners, Inc.

NasdaqGS:SGRY Voorraadrapport

Marktkapitalisatie: US$2.9b

Surgery Partners Toekomstige groei

Future criteriumcontroles 4/6

Surgery Partners zal naar verwachting groeien in winst en omzet met respectievelijk 83.5% en 9.3% per jaar. De winst per aandeel zal naar verwachting groeien met 85.6% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 8.2% zijn.

Belangrijke informatie

83.5%

Groei van de winst

85.6%

Groei van de winst per aandeel

Healthcare winstgroei20.9%
Inkomstengroei9.3%
Toekomstig rendement op eigen vermogen8.2%
Dekking van analisten

Good

Laatst bijgewerkt25 Nov 2024

Recente toekomstige groei-updates

Recent updates

Surgery Partners (NASDAQ:SGRY) Takes On Some Risk With Its Use Of Debt

Nov 11
Surgery Partners (NASDAQ:SGRY) Takes On Some Risk With Its Use Of Debt

Market Cool On Surgery Partners, Inc.'s (NASDAQ:SGRY) Revenues

Oct 24
Market Cool On Surgery Partners, Inc.'s (NASDAQ:SGRY) Revenues

Surgery Partners (NASDAQ:SGRY) Has Some Way To Go To Become A Multi-Bagger

Oct 05
Surgery Partners (NASDAQ:SGRY) Has Some Way To Go To Become A Multi-Bagger

Surgery Partners, Inc. (NASDAQ:SGRY) Soars 25% But It's A Story Of Risk Vs Reward

Jul 25
Surgery Partners, Inc. (NASDAQ:SGRY) Soars 25% But It's A Story Of Risk Vs Reward

Here's Why Surgery Partners (NASDAQ:SGRY) Has A Meaningful Debt Burden

Jul 13
Here's Why Surgery Partners (NASDAQ:SGRY) Has A Meaningful Debt Burden

Slowing Rates Of Return At Surgery Partners (NASDAQ:SGRY) Leave Little Room For Excitement

Jun 21
Slowing Rates Of Return At Surgery Partners (NASDAQ:SGRY) Leave Little Room For Excitement

We Think Shareholders Are Less Likely To Approve A Pay Rise For Surgery Partners, Inc.'s (NASDAQ:SGRY) CEO For Now

May 31
We Think Shareholders Are Less Likely To Approve A Pay Rise For Surgery Partners, Inc.'s (NASDAQ:SGRY) CEO For Now

Surgery Partners, Inc.'s (NASDAQ:SGRY) Share Price Matching Investor Opinion

Apr 24
Surgery Partners, Inc.'s (NASDAQ:SGRY) Share Price Matching Investor Opinion

Surgery Partners' (NASDAQ:SGRY) Returns Have Hit A Wall

Mar 18
Surgery Partners' (NASDAQ:SGRY) Returns Have Hit A Wall

Surgery Partners (NASDAQ:SGRY) Takes On Some Risk With Its Use Of Debt

Feb 27
Surgery Partners (NASDAQ:SGRY) Takes On Some Risk With Its Use Of Debt

The Price Is Right For Surgery Partners, Inc. (NASDAQ:SGRY)

Dec 19
The Price Is Right For Surgery Partners, Inc. (NASDAQ:SGRY)

Returns Are Gaining Momentum At Surgery Partners (NASDAQ:SGRY)

Oct 26
Returns Are Gaining Momentum At Surgery Partners (NASDAQ:SGRY)

Does Surgery Partners (NASDAQ:SGRY) Have A Healthy Balance Sheet?

Sep 17
Does Surgery Partners (NASDAQ:SGRY) Have A Healthy Balance Sheet?

Are Investors Undervaluing Surgery Partners, Inc. (NASDAQ:SGRY) By 35%?

Aug 26
Are Investors Undervaluing Surgery Partners, Inc. (NASDAQ:SGRY) By 35%?

The Return Trends At Surgery Partners (NASDAQ:SGRY) Look Promising

Jul 21
The Return Trends At Surgery Partners (NASDAQ:SGRY) Look Promising

Surgery Partners, Inc.'s (NASDAQ:SGRY) Shareholders Might Be Looking For Exit

Jun 15
Surgery Partners, Inc.'s (NASDAQ:SGRY) Shareholders Might Be Looking For Exit

A Look At The Intrinsic Value Of Surgery Partners, Inc. (NASDAQ:SGRY)

May 26
A Look At The Intrinsic Value Of Surgery Partners, Inc. (NASDAQ:SGRY)

There's Been No Shortage Of Growth Recently For Surgery Partners' (NASDAQ:SGRY) Returns On Capital

Apr 14
There's Been No Shortage Of Growth Recently For Surgery Partners' (NASDAQ:SGRY) Returns On Capital

Surgery Partners (NASDAQ:SGRY) Has A Somewhat Strained Balance Sheet

Mar 24
Surgery Partners (NASDAQ:SGRY) Has A Somewhat Strained Balance Sheet

Surgery Partners, Inc. (NASDAQ:SGRY) Shares Could Be 50% Below Their Intrinsic Value Estimate

Jan 24
Surgery Partners, Inc. (NASDAQ:SGRY) Shares Could Be 50% Below Their Intrinsic Value Estimate

We Think Surgery Partners (NASDAQ:SGRY) Is Taking Some Risk With Its Debt

Sep 26
We Think Surgery Partners (NASDAQ:SGRY) Is Taking Some Risk With Its Debt

The Returns On Capital At Surgery Partners (NASDAQ:SGRY) Don't Inspire Confidence

Aug 15
The Returns On Capital At Surgery Partners (NASDAQ:SGRY) Don't Inspire Confidence

Surgery Partners GAAP EPS of -$0.21 misses by $0.07, revenue of $615.4M misses by $3.61M

Aug 02

Surgery Partners And Alternative Near Cap-Gain Portfolio Wealth Builders

Jul 02

Surgery Partners (NASDAQ:SGRY) Takes On Some Risk With Its Use Of Debt

Jun 27
Surgery Partners (NASDAQ:SGRY) Takes On Some Risk With Its Use Of Debt

Winst- en omzetgroeiprognoses

NasdaqGS:SGRY - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/20263,69615433934610
12/31/20253,38511129739912
12/31/20243,079-2716526611
9/30/20242,985-61163251N/A
6/30/20242,889-34204291N/A
3/31/20242,7951175260N/A
12/31/20232,743-12205294N/A
9/30/20232,715-34147238N/A
6/30/20232,662-5473164N/A
3/31/20232,609-9267154N/A
12/31/20222,539-5578159N/A
9/30/20222,442-3199171N/A
6/30/20222,381-2986157N/A
3/31/20222,309-3855117N/A
12/31/20212,225-813087N/A
9/30/20212,163-861876N/A
6/30/20212,100-1353788N/A
3/31/20211,932-150222268N/A
12/31/20201,860-156204247N/A
9/30/20201,829-179212263N/A
6/30/20201,785-132232293N/A
3/31/20201,856-11965138N/A
12/31/20191,831-11056130N/A
9/30/20191,805-23886150N/A
6/30/20191,786-24367122N/A
3/31/20191,777-24194135N/A
12/31/20181,772-238105145N/A
9/30/20181,732-122118154N/A
6/30/20181,597-125N/A134N/A
3/31/20181,443-102N/A116N/A
12/31/20171,312-79N/A121N/A
9/30/20171,159-22N/A99N/A
6/30/20171,1357N/A108N/A
3/31/20171,13914N/A135N/A
12/31/20161,1219N/A125N/A
9/30/20161,0799N/A117N/A
6/30/20161,0399N/A128N/A
3/31/20169811N/A100N/A
12/31/20159361N/A84N/A
9/30/2015855-70N/A53N/A
6/30/2015696-73N/A38N/A
3/31/2015544-69N/A27N/A
12/31/2014394-66N/A22N/A
12/31/2013279-9N/A49N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat SGRY de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 2.6% ).

Winst versus markt: Er wordt verwacht dat SGRY de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat SGRY binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van SGRY ( 9.3% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van SGRY ( 9.3% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen SGRY zal naar verwachting over 3 jaar laag zijn ( 8.2 %).


Ontdek groeibedrijven